Human Papillomavirus Minor Capsid Protein L2 (L2) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

L2 is a minor capsid component and lacks the capacity to form VLPs. This protein plays a role in capsid stabilization through interaction with the major capsid protein L1. The Human Papillomavirus Minor Capsid Protein L2 (L2) Development market research report provides an in-depth analysis of Human Papillomavirus Minor Capsid Protein L2 (L2) targeted pipeline therapeutics. The report provides comprehensive information on the Human Papillomavirus Minor Capsid Protein L2 (L2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type.

The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in Human Papillomavirus Minor Capsid Protein L2 (L2) targeted therapeutics development with respective active and dormant or discontinued projects.

Routes of Administration in Human Papillomavirus Minor Capsid Protein L2 Pipeline Market

The route of administration in the Human Papillomavirus Minor Capsid Protein L2 pipeline market is intramuscular.

Molecule Types in Human Papillomavirus Minor Capsid Protein L2 Pipeline Market

The molecule types in the Human Papillomavirus Minor Capsid Protein L2 pipeline market are subunit vaccine, DNA vaccine, and vaccine.

Human Papillomavirus Minor Capsid Protein L2 pipeline market, by molecule types

Human Papillomavirus Minor Capsid Protein L2 pipeline market, by molecule types

For more molecule type insights, download a free report sample

Key Human Papillomavirus Minor Capsid Protein L2 Pipeline Market Companies

The key companies in the Human Papillomavirus Minor Capsid Protein L2 pipeline market are 2A Pharma AB, Papivax LLC, and Pathovax LLC.

Human Papillomavirus Minor Capsid Protein L2 pipeline market, by companies

Human Papillomavirus Minor Capsid Protein L2 pipeline market, by companies

To know more about key companies, download a free report sample

Market report overview

Routes of Administration Intramuscular
Molecule Types Subunit Vaccine, DNA Vaccine, and Vaccine
Key Companies 2A Pharma AB, Papivax LLC, and Pathovax LLC

Scope

 This report provides:

  • A snapshot of the global therapeutic landscape of Human Papillomavirus Minor Capsid Protein L2 (L2).
  • Reviews of Human Papillomavirus Minor Capsid Protein L2 (L2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products based on various stages of development ranging from pre-registration to discovery and undisclosed stages.
  • Descriptive drug profiles for the pipeline products which include product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities.
  • Reviews of key players involved in Human Papillomavirus Minor Capsid Protein L2 (L2) therapeutics and enlists all their major and minor projects.
  • Assessment of Human Papillomavirus Minor Capsid Protein L2 (L2) targeted therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA), and molecule type.
  • All the dormant and discontinued pipeline projects.
  • Reviews of the latest news and deals related to pipeline therapeutics for Human Papillomavirus Minor Capsid Protein L2 (L2).

Reasons to Buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies.
  • Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage.
  • Identify and understand the targeted therapy areas and indications for Human Papillomavirus Minor Capsid Protein L2 (L2).
  • Identify the use of drugs for target identification and drug repurposing.
  • Identify potential new clients or partners in the target demographic.
  • Develop strategic initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions effectively by identifying key players and their most promising pipeline therapeutics.
  • Devise corrective measures for pipeline projects by understanding Human Papillomavirus Minor Capsid Protein L2 (L2) development landscape.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

2A Pharma AB
Papivax LLC
Pathovax LLC

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Human Papillomavirus Minor Capsid Protein L2 (L2) – Overview

Human Papillomavirus Minor Capsid Protein L2 (L2) – Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Human Papillomavirus Minor Capsid Protein L2 (L2) – Therapeutics Assessment

Assessment by Route of Administration

Assessment by Molecule Type

Human Papillomavirus Minor Capsid Protein L2 (L2) – Companies Involved in Therapeutics Development

2A Pharma AB

Papivax LLC

Pathovax LLC

Human Papillomavirus Minor Capsid Protein L2 (L2) – Drug Profiles

2AP-01 – Drug Profile

Product Description

Mechanism Of Action

History of Events

PANHPVAX – Drug Profile

Product Description

Mechanism Of Action

History of Events

PVX-01 – Drug Profile

Product Description

Mechanism Of Action

History of Events

PVX-2 – Drug Profile

Product Description

Mechanism Of Action

History of Events

RGVax – Drug Profile

Product Description

Mechanism Of Action

History of Events

TA-CIN – Drug Profile

Product Description

Mechanism Of Action

History of Events

Human Papillomavirus Minor Capsid Protein L2 (L2) – Dormant Products

Human Papillomavirus Minor Capsid Protein L2 (L2) – Discontinued Products

Human Papillomavirus Minor Capsid Protein L2 (L2) – Product Development Milestones

Featured News & Press Releases

Dec 01, 2021: Jeanette presents E-poster at IPVC 2021

Nov 25, 2019: 2A Pharma announces the completion of dosing for 2AP01 vaccine

Mar 02, 2019: 2A Pharma initiates phase 1 clinical trial of HPV vaccine candidate

Dec 14, 2018: 2A Pharma receives approval for phase 1 study of 2AP-01

Apr 17, 2018: As DKFZ’s HPV vaccine candidate based on Osivax’s technology platform (OVX313) reports promising pre-clinical results, a second license agreement was signed

Oct 27, 2016: PathoVax Wins $500,000 in 43North Contest

Oct 30, 2014: National Cancer Institute supports next-generation Austrian HPV vaccine

Sep 10, 2013: New, Even More Effective HPV Vaccine In Sight

Apr 10, 2012: Medigene Presents Preclinical AAVLP Data At World Vaccine Congress

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Products under Development by Stage of Development, 2022

Number of Products under Development by Therapy Areas, 2022

Number of Products under Development by Indication, 2022

Number of Products under Development by Companies, 2022

Products under Development by Companies, 2022

Number of Products under Investigation by Universities/Institutes, 2022

Products under Investigation by Universities/Institutes, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Pipeline by 2A Pharma AB, 2022

Pipeline by Papivax LLC, 2022

Pipeline by Pathovax LLC, 2022

Dormant Projects, 2022

Discontinued Products, 2022

Figures

List of Figures

Number of Products under Development by Stage of Development, 2022

Number of Products under Development by Therapy Areas, 2022

Number of Products under Development by Indications, 2022

Number of Products by Molecule Types, 2022

Number of Products by Molecule Types, 2022

Number of Products by Stage and Molecule Types, 2022

Frequently asked questions

Human Papillomavirus Minor Capsid Protein L2 (L2) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update thematic reports
Currency USD
$3,500

Can be used by individual purchaser only

$10,500

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Human Papillomavirus Minor Capsid Protein L2 (L2) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Human Papillomavirus Minor Capsid Protein L2 (L2) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live Human Papillomavirus Minor Capsid Protein L2 (L2) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.